-
Ultimovacs ASA: Third quarter 2021 result presentation
-
Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma
-
Ultimovacs ASA: Invitation to third quarter 2021 results presentation
-
Ultimovacs ASA – New share capital registered
-
Ultimovacs ASA – Transactions by primary insiders and closely associated parties
-
Ultimovacs ASA – Private placement of new shares successfully placed
-
Ultimovacs ASA – Private placement of new shares successfully placed
-
Ultimovacs ASA – Contemplated private placement
-
Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)
-
Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma
